Advertisement

Biological Basis of Treatment Failure

  • Amritha SureshEmail author
  • Ram Bhupal Reddy
  • Bonney Lee James
  • Moni Abraham Kuriakose
Chapter

Abstract

Despite aggressive multimodality treatment, over 50 % of oral cancers develop disease recurrence. Majority of the recurrence develop at the primary site. However intensification of locoregional therapy especially with the use of postoperative adjuvant chemoradiotherapy, a higher proportion of disease failures, is seen at the distant site. Recurrent disease is often resistant to treatment and often an indicator of incurability, especially those with metastatic disease. Mechanism of disease recurrence following surgery and chemoradiotherapy is different.

Keywords

Neck Cancer Cancer Stem Cell COX2 Expression Phosphatidic Acid mTOR Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hockel M, Dornhöfer N. The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. Cancer Res. 2005;65(8):2997.PubMedGoogle Scholar
  2. 2.
    Ceradini DJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10(8):858–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66(9):4553–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Reid SE, et al. Perioperative stimulation of residual cancer cells promotes local and distant recurrence of breast cancer. J Am Coll Surg. 1997;185(3):290–306.PubMedCrossRefGoogle Scholar
  6. 6.
    Abramovitch R, et al. Stimulation of tumour angiogenesis by proximal wounds: spatial and temporal analysis by MRI. Br J Cancer. 1998;77(3):440–7.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Holmstrup P. Can we prevent malignancy by treating premalignant lesions? Oral Oncol. 2009;45(7):549–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Lu HP, Chao CC. Cancer cells acquire resistance to anticancer drugs: an update. Biomed J. 2012;35(6):464–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Ansell A, et al. Matrix metalloproteinase-7 and -13 expression associate to cisplatin resistance in head and neck cancer cell lines. Oral Oncol. 2009;45(10):866–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Syed N, et al. PMID: 25327479 PMCID: PMC4528963 DOI: 10.1002/pmic.201400338.Google Scholar
  11. 11.
    Zhang P, et al. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer. 2006;6:224.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Dai Y, et al. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck. 2011;33(6):786–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Nozawa H, et al. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci. 2006;97(10):1115–24.PubMedCrossRefGoogle Scholar
  14. 14.
    SV, et al. Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines. Mol Med Rep. 2015;12(2):3025–32.Google Scholar
  15. 15.
    Blons H, et al. Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. Int J Cancer. 1999;84(4):410–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Cabelguenne A, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol. 2000;18(7):1465–73.PubMedGoogle Scholar
  17. 17.
    Sahoo R, et al. Relationship between molecular markers and treatment response in a retrospective cohort of Indian patients with primary carcinoma of the larynx. Oral Oncol. 2009;45(12):e216–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Kudo I, et al. p53 mutation, but not in vitro predictor genes of therapeutic efficacy of cisplatin, is clinically relevant in comparing partial and complete responder cases of maxillary squamous cell carcinoma. Oncol Rep. 2010;24(4):851–6.PubMedGoogle Scholar
  19. 19.
    Bergamaschi D, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3(4):387–402.PubMedCrossRefGoogle Scholar
  20. 20.
    Shiga H, et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res. 1999;5(12):4097–104.PubMedGoogle Scholar
  21. 21.
    Nishimura T, et al. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res. 1996;2(11):1859–65.PubMedGoogle Scholar
  22. 22.
    Koukourakis MI, et al. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res. 2000;6(2):381–9.PubMedGoogle Scholar
  23. 23.
    Leng WD, et al. Expression and implication of Pgp, MRP, LRP, GST-pi, Topo II alpha in tongue squamous cell carcinoma. Hua Xi Kou Qiang Yi Xue Za Zhi. 2004;22(1):23–5.PubMedGoogle Scholar
  24. 24.
    Ng IO, et al. Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma. Cancer. 1998;83(5):851–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Mannarini L, et al. Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation. Acta Otorhinolaryngol Ital. 2007;27(4):173–80.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Hsu DS, et al. Regulation of excision repair cross-complementation group 1 by snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 2010;16(18):4561–71.PubMedCrossRefGoogle Scholar
  27. 27.
    De Castro Jr G, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep. 2011;25(3):693–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Chiu TJ, et al. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J Transl Med. 2011;9:31.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Vaezi A, et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2011;17(16):5513–22.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Feng Z, et al. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS One. 2011;6(10):e26399.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Michaud WA, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2009;15(5):1645–54.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Yang XH, et al. XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer. PLoS One. 2012;7(3):e31601.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Monzo M, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 1999;17(6):1786–93.PubMedGoogle Scholar
  34. 34.
    Blons H, et al. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res. 2004;10(8):2594–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Shiga H, et al. Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer. Head Neck. 2000;22(6):599–608.PubMedCrossRefGoogle Scholar
  36. 36.
    Ogawa T, et al. miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. Cancer Sci. 2012;103(9):1737–43.PubMedCrossRefGoogle Scholar
  37. 37.
    Zhong LP, et al. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther. 2013;12(6):1112–21.PubMedCrossRefGoogle Scholar
  38. 38.
    Yang CZ, et al. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma. Ann Oncol. 2014;25(6):1215–22.PubMedCrossRefGoogle Scholar
  39. 39.
    Zhu DW, et al. Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade. BMC Cancer. 2013;13:301.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Fan XS, et al. Immunohistochemistry using epidermal growth factor receptor mutation-specific antibodies of delE746-A750 and L858R in lung adenocarcinomas. Zhonghua Bing Li Xue Za Zhi. 2013;42(3):173–7.PubMedGoogle Scholar
  41. 41.
    Park Y, et al. RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Onkologie. 2012;35(11):673–82.PubMedCrossRefGoogle Scholar
  42. 42.
    Cullen KJ, et al. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol. 2009;27(36):6222–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Wu Y, et al. Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial. Cancer. 2012;118(7):1811–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Govindan SV, et al. Acquisition of cancer stem cell behaviour plays a role in drug resistance to combination chemotherapy and prognosis in head and neck cancer. J Stem Cell Res Ther. 2015. 5(1). http://dx.doi.org/10.4172/2157-7633.1000261.
  45. 45.
    Abrahao AC, et al. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma. J Oral Pathol Med. 2013. doi: 10.1111/jop.12081.PubMedGoogle Scholar
  46. 46.
    Ramakrishnan MS, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 2009;1(1):41–8.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Loeffler-Ragg J, et al. EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2008;17(10):1517–31.PubMedCrossRefGoogle Scholar
  48. 48.
    Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2006;6(8):691–710.PubMedCrossRefGoogle Scholar
  49. 49.
    Gallo O, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 2001;3(1):53–61.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Shin DM, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res. 2013;19(5):1244–56.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Zweifel BS, et al. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 2002;62(22):6706–11.PubMedGoogle Scholar
  52. 52.
    Blick SK, Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs. 2007;67(17):2585–607.PubMedCrossRefGoogle Scholar
  53. 53.
    Boeckx C, et al. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. Oncologist. 2013;18(7):850–64.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Choong NW, Cohen EE. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol. 2006;57(1):25–43.PubMedCrossRefGoogle Scholar
  55. 55.
    Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389–400.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Vincenzi B, et al. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 2010;10(1):80–95.PubMedCrossRefGoogle Scholar
  57. 57.
    Burtness B, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(34):8646–54.PubMedCrossRefGoogle Scholar
  58. 58.
    Licitra L, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013;49(6):1161–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Psyrri A, et al. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: eastern cooperative oncology group E2303. Clin Cancer Res. 2014;20(11):3023–32.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Licitra L, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011;22(5):1078–87.PubMedCrossRefGoogle Scholar
  61. 61.
    Tejani MA, Cohen RB, Mehra R. The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biol Targets Ther. 2010;4:173–85.Google Scholar
  62. 62.
    Argiris A, et al. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol. 2011;47(10):961–6.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Smilek P, et al. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. Neoplasma. 2012;59(5):508–15.PubMedCrossRefGoogle Scholar
  64. 64.
    Chung CH, et al. A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2014;25(11):2230–6.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Lin YC, et al. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol. 2012;48(7):585–93.PubMedCrossRefGoogle Scholar
  66. 66.
    Junttila MR, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130(1):51–62.PubMedCrossRefGoogle Scholar
  67. 67.
    Maertens O, Cichowski K. Paths of resistance to EGFR inhibitors: is NF enough? Cancer Discov. 2014;4(5):519–21.PubMedCrossRefGoogle Scholar
  68. 68.
    de Bruin EC, et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 2014;4(5):606–19.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Upadhyaya M. Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Front Biosci (Landmark Ed). 2011;16:937–51.CrossRefGoogle Scholar
  70. 70.
    Boeckx C, et al. Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins. Cancer Lett. 2014;354(2):365–77.PubMedCrossRefGoogle Scholar
  71. 71.
    McCubrey JA, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012;3(9):954–87.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    D’Amato V, et al. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. Br J Cancer. 2014;110(12):2887–95.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Pickhard A, et al. PMID: 24980817 PMCID: PMC4170642 DOI:  10.18632/oncotarget.2117.
  74. 74.
    Thomas F, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13(23):7086–92.PubMedCrossRefGoogle Scholar
  75. 75.
    Dennis M, et al. Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells. Otolaryngol Head Neck Surg. 2012;147(4):726–32.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Frederick BA, et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007;6(6):1683–91.PubMedCrossRefGoogle Scholar
  77. 77.
    Godin-Heymann N, et al. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther. 2008;7(4):874–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Grau JJ, et al. Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study. Acta Otolaryngol. 2007;127(1):71–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Chan G, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(5):991–4.PubMedGoogle Scholar
  80. 80.
    Chen SZ, Zhen YS. Molecular targets of tea polyphenols and its roles of anticancer drugs in experimental therapy. Yao Xue Xue Bao. 2013;48(1):1–7.PubMedGoogle Scholar
  81. 81.
    Mestre JR, et al. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann N Y Acad Sci. 1999;889:62–71.PubMedCrossRefGoogle Scholar
  82. 82.
    Gallo O, et al. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002;33(7):708–14.PubMedCrossRefGoogle Scholar
  83. 83.
    Abrahao AC, et al. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol. 2010;46(12):880–7.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Sawaoka H, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest. 1999;79(12):1469–77.PubMedGoogle Scholar
  85. 85.
    Fu SL, et al. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol. 2004;10(13):1971–4.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Jiang XH, Wong BC. Cyclooxygenase-2 inhibition and gastric cancer. Curr Pharm Des. 2003;9(27):2281–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Sawaoka H, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol. 1998;274(6 Pt 1):G1061–7.PubMedGoogle Scholar
  88. 88.
    Tuynman JB, et al. Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma. Ned Tijdschr Geneeskd. 2003;147(45):2207–12.PubMedGoogle Scholar
  89. 89.
    Kao J, Sikora AT, Fu S. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Curr Cancer Drug Targets. 2009;9(8):931–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope. 2002;112(5):839–43.PubMedCrossRefGoogle Scholar
  91. 91.
    Chen Z, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10(17):5930–9.PubMedCrossRefGoogle Scholar
  92. 92.
    Hashitani S, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol. 2003;23(3):665–72.PubMedGoogle Scholar
  93. 93.
    Fu S, et al. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 as a novel approach to enhance radiotherapy. J Cell Sci Ther. 2011;1(2). pii: S1–002.Google Scholar
  94. 94.
    Qian M, et al. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncol Rep. 2014;32(4):1681–8.PubMedGoogle Scholar
  95. 95.
    Choe MS, et al. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13(10):3015–23.PubMedCrossRefGoogle Scholar
  96. 96.
    Abrahao AC, et al. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma. J Oral Pathol Med. 2013;42(10):793–8.PubMedCrossRefGoogle Scholar
  97. 97.
    St John MA. Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma. Laryngoscope. 2015;125 Suppl 3:S1–11.PubMedCrossRefGoogle Scholar
  98. 98.
    Dong GW, Do NY, Lim SC. Relation between proinflammatory mediators and epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Exp Ther Med. 2010;1(5):885–91.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Saba NF, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila). 2014;7(3):283–91.CrossRefGoogle Scholar
  100. 100.
    Kao J, et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer. 2011;117(14):3173–81.PubMedCrossRefGoogle Scholar
  101. 101.
    Raju U, et al. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys. 2005;63(2):520–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Hamakawa H, et al. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck. 2008;30(6):800–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Hildebrandt MA, et al. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012;18(13):3705–13.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Nathan CO, et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2004;10(17):5820–7.PubMedCrossRefGoogle Scholar
  105. 105.
    Nathan CO, et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 2007;67(5):2160–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Ye L, et al. Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. Front Genet. 2012;3:177.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Toschi A, et al. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009;29(6):1411–20.PubMedCrossRefGoogle Scholar
  108. 108.
    Rosborough BR, et al. Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. Blood. 2013;121(18):3619–30.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Chakraborty S, et al. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer. 2008;8:163.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Gao W, et al. mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer. International Scholarly Research Network, 2012, doi:  10.5402/2012/953089.
  111. 111.
    Italiano A, et al. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer. 2012;118(23):5878–87.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Czerninski R, et al. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila). 2009;2(1):27–36.CrossRefGoogle Scholar
  113. 113.
    Liao YM, Kim C, Yen Y. Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head Neck Oncol. 2011;3:22.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Patel V, et al. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res. 2011;71(22):7103–12.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Roca H, Varsos ZS, Pienta KJ. CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. Neoplasia. 2009;11(12):1309–17.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Luangdilok S, et al. MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck. Eur J Cancer. 2011;47(4):520–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Aissat N, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol. 2008;62(2):305–13.PubMedCrossRefGoogle Scholar
  118. 118.
    Bouali S, et al. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep. 2009;21(3):731–5.PubMedGoogle Scholar
  119. 119.
    Lee S, et al. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005;97(1):26–34.PubMedCrossRefGoogle Scholar
  120. 120.
    Frondorf K, et al. Phosphatidic acid is a leukocyte chemoattractant that acts through S6 kinase signaling. J Biol Chem. 2010;285(21):15837–47.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Gomez-Cambronero J. The exquisite regulation of PLD2 by a wealth of interacting proteins: S6K, Grb2, Sos, WASp and Rac2 (and a surprise discovery: PLD2 is a GEF). Cell Signal. 2011;23(12):1885–95.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Lehman N, et al. Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR. Faseb J. 2007;21(4):1075–87.PubMedCrossRefGoogle Scholar
  123. 123.
    Taga M, et al. Modulation of oxidative stress and tau phosphorylation by the mTOR activator phosphatidic acid in SH-SY5Y cells. FEBS Lett. 2011;585(12):1801–6.PubMedCrossRefGoogle Scholar
  124. 124.
    Fang Y, et al. PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1. Curr Biol. 2003;13(23):2037–44.PubMedCrossRefGoogle Scholar
  125. 125.
    Sun D, et al. Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines. Sci China C Life Sci. 2008;51(7):640–7.PubMedCrossRefGoogle Scholar
  126. 126.
    You JS, Frey JW, Hornberger TA. Mechanical stimulation induces mTOR signaling via an ERK-independent mechanism: implications for a direct activation of mTOR by phosphatidic acid. PLoS One. 2012;7(10):e47258.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Massarelli E, et al. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015;26(7):1476–80.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Amritha Suresh
    • 1
    • 2
    Email author
  • Ram Bhupal Reddy
    • 1
    • 2
  • Bonney Lee James
    • 1
    • 2
  • Moni Abraham Kuriakose
    • 1
    • 2
  1. 1.Integrated Head and Neck Oncology Program DSRG-5Mazumdar Shaw Center for Translational Research, Mazumdar Shaw Medical CentreBangaloreIndia
  2. 2.Department of Head and Neck/Plastic & Reconstructive SurgeryRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations